IBO
Beyond's analysis on IBO
Recent news mentioning IBO
- — CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
- — GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
- — GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
- — Family Care Center Opens New Cibolo Clinic, Expanding Behavioral Health Care in San Antonio Area
- — FairJourney Bio Consolidates Antibody Discovery Data with the Sapio Sciences Scientific AI Platform
- — TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
- — Osisko Gold Announces Formal Construction Decision and Development Update for the Cariboo Gold Project
- — Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
- — Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
- — Korea University Study Uncovers How mRNA Vaccination May Broaden Flu Antibody Responses
- — PolarX Announces Hyper Copper Grades Over Big Widths from Surface Point to Significant Resource Growth at Caribou Dome Project
- — The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome